Bloomberg Intelligence cover image

Novo Nordisk Gets US Approval for Wegovy Obesity Pill 

Bloomberg Intelligence

00:00

Novo Nordisk's recent setbacks and stock impact

Hosts review the failed next-gen candidate and how it affected Novo's stock and strategy.

Play episode from 07:13
Transcript

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app